Opinion|Videos|January 21, 2025
Discussing Treatment Options for BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how treatment decisions involve balancing clinical efficacy with financial considerations, noting that patients often prefer treatments with fewer office visits and minimal lifestyle disruption when presented with multiple effective options.
Advertisement
Episodes in this series
- What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies?
- With all the available treatments on market, what are your patient preferences when it comes to treatment experiences?
- With all the available treatments on market, what are your patient preferences when it comes to treatment experiences?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5
